Compounds > pyrazolanthrone
Page last updated: 2024-08-18

pyrazolanthrone and Idiopathic Parkinson Disease

pyrazolanthrone has been researched along with Idiopathic Parkinson Disease in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lu, BX; Luo, YF; Man, RY; Wang, XF; Zeng, QG; Zeng, Y1
Li, H; Wang, Y; Wei, Z; Zhang, Y; Zhang, Z; Zhou, H1
Liedhegner, EA; Mieyal, JJ; Steller, KM1
Arenas, E; Castelo-Branco, G; Parish, C; Rawal, N1
Tian, QY; Wang, YS; Wei, ZF; Zhang, YX; Zhou, HX; Zhou, JP1

Other Studies

5 other study(ies) available for pyrazolanthrone and Idiopathic Parkinson Disease

ArticleYear
Induction of GADD45α protects M17 neuroblastoma cells against MPP*.
    IUBMB life, 2014, Volume: 66, Issue:11

    Topics: 1-Methyl-4-phenylpyridinium; Analysis of Variance; Anthracenes; Blotting, Western; Caspase 3; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Chromatin Immunoprecipitation; Dose-Response Relationship, Drug; Gene Expression Regulation; Humans; Imidazoles; In Situ Nick-End Labeling; Nuclear Proteins; Parkinson Disease; Pyridines; Real-Time Polymerase Chain Reaction; RNA Interference; Tetrazolium Salts; Thiazoles

2014
JNK inhibitor protects dopaminergic neurons by reducing COX-2 expression in the MPTP mouse model of subacute Parkinson's disease.
    Journal of the neurological sciences, 2009, Oct-15, Volume: 285, Issue:1-2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anthracenes; Cell Death; Cyclooxygenase 2; Disease Models, Animal; Dopamine; Enzyme Inhibitors; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Movement Disorders; Neurons; Parkinson Disease; Parkinsonian Disorders; Phosphorylation; Proto-Oncogene Proteins c-jun; Random Allocation; Substantia Nigra

2009
Levodopa activates apoptosis signaling kinase 1 (ASK1) and promotes apoptosis in a neuronal model: implications for the treatment of Parkinson's disease.
    Chemical research in toxicology, 2011, Oct-17, Volume: 24, Issue:10

    Topics: Anthracenes; Antiparkinson Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Survival; Dopaminergic Neurons; Enzyme Inhibitors; Gene Knockdown Techniques; Humans; Imidazoles; JNK Mitogen-Activated Protein Kinases; Levodopa; MAP Kinase Kinase Kinase 5; NF-kappa B; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Parkinson Disease; Pyridines

2011
Inhibition of JNK increases survival of transplanted dopamine neurons in Parkinsonian rats.
    Cell death and differentiation, 2007, Volume: 14, Issue:2

    Topics: Animals; Anthracenes; Cell Survival; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Graft Survival; JNK Mitogen-Activated Protein Kinases; Mesencephalon; Neurons; Parkinson Disease; Rats; Tyrosine 3-Monooxygenase

2007
[Effect of phosphorylated c-Jun expression on COX-2 expression in the substantia nigra of MPTP mouse model of subacute Parkinson disease].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2007, Volume: 27, Issue:8

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anthracenes; Blotting, Western; Cell Death; Cyclooxygenase 2; Disease Models, Animal; Dopamine; Gene Expression Regulation, Enzymologic; Humans; Immunohistochemistry; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Neurons; Parkinson Disease; Phosphoproteins; Phosphorylation; Proto-Oncogene Proteins c-jun; Substantia Nigra

2007